| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Borchelt DR | |
| Price DL | |||
| Sisodia SS | |||
| P2860 | cites work | Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis | Q24306886 |
| Life and death of neurons in the aging brain | Q41614205 | ||
| P433 | issue | 5391 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neurodegeneration | Q1755122 |
| P304 | page(s) | 1079-1083 | |
| P577 | publication date | 1998-11-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | Genetic neurodegenerative diseases: the human illness and transgenic models | |
| P478 | volume | 282 |
| Q49049294 | A gain-of-function mutation in the sodium channel gene Scn2a results in seizures and behavioral abnormalities |
| Q51968465 | A pharmacogenomic approach to Alzheimer's disease. |
| Q24300117 | AATF inhibits aberrant production of amyloid beta peptide 1-42 by interacting directly with Par-4 |
| Q48430406 | Abeta conformational change is central to Alzheimer's disease |
| Q35009763 | Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease |
| Q34013197 | Adeno-associated virus effectively mediates conditional gene modification in the brain |
| Q45740016 | Adeno-associated virus vector-mediated gene transfer to somatic cells in the central nervous system |
| Q54965150 | Advances in genetic models of Parkinson's disease |
| Q46084355 | Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. |
| Q30492443 | Amyloid precursor protein increases cortical neuron size in transgenic mice |
| Q35048032 | Amyotrophic lateral sclerosis: progress and prospects for treatment |
| Q37016107 | An update on the pharmacology of galantamine |
| Q44735300 | Analyzing corticosterone metabolites in fecal samples of mice: a noninvasive technique to monitor stress hormones |
| Q44188025 | Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine |
| Q28142812 | Antioxidant enzymes and human diseases |
| Q36301441 | Apoptotic activities of wild-type and Alzheimer's disease-related mutant presenilins in Drosophila melanogaster |
| Q30847227 | Behavioral Senescence and Aging-Related Changes in Motor Neurons and Brain Neuromodulator Levels Are Ameliorated by Lifespan-Extending Reproductive Dormancy in Drosophila. |
| Q89495923 | Benefits of aged garlic extract on Alzheimer's disease: Possible mechanisms of action |
| Q42522365 | Beta-amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for beta-secretase activity in chromaffin vesicles |
| Q38854247 | Bridging the gap: large animal models in neurodegenerative research |
| Q33971339 | Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide |
| Q47859815 | Consumption of fig fruits grown in Oman can improve memory, anxiety, and learning skills in a transgenic mice model of Alzheimer's disease. |
| Q37946750 | Continuing pursuit for ideal systemic anticancer radiotherapeutics |
| Q38419073 | DC2 and keratinocyte-associated protein 2 (KCP2), subunits of the oligosaccharyltransferase complex, are regulators of the gamma-secretase-directed processing of amyloid precursor protein (APP). |
| Q34137277 | Death by necrosis. Uncontrollable catastrophe, or is there order behind the chaos? |
| Q43645646 | Demyelination, astrogliosis, and accumulation of ubiquitinated proteins, hallmarks of CNS disease in hsf1-deficient mice. |
| Q33760943 | Developing mouse models of aging: a consideration of strain differences in age-related behavioral and neural parameters |
| Q34452604 | Development of lipophilic cations as therapies for disorders due to mitochondrial dysfunction |
| Q33853014 | Drug delivery to mitochondria: the key to mitochondrial medicine |
| Q38306321 | ER stress signaling and neurodegeneration: At the intersection between Alzheimer's disease and Prion-related disorders |
| Q34088828 | Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology |
| Q40203503 | Endoplasmic reticulum chaperones inhibit the production of amyloid-beta peptides. |
| Q46480001 | Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice. |
| Q48540561 | Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice |
| Q44030457 | Expression and characterization of the Drosophila X11-like/Mint protein during neural development |
| Q82239887 | Expression of a familial Alzheimer's disease-linked presenilin-1 variant enhances perforant pathway lesion-induced neuronal loss in the entorhinal cortex |
| Q35750194 | Familial encephalopathy with neuroserpin inclusion bodies |
| Q48546153 | Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. |
| Q35672366 | Functional aspects of cellular microcompartmentation in the development of neurodegeneration: mutation induced aberrant protein-protein associations |
| Q39983630 | Gamma irradiation of human leukaemic cells HL-60 and MOLT-4 induces decrease in Mcl-1 and Bid, release of cytochrome c, and activation of caspase-8 and caspase-9. |
| Q44235491 | Generation of aberrant sprouting in the adult rat brain by GAP-43 somatic gene transfer |
| Q34350636 | Genetic models of mechanotransduction: the nematode Caenorhabditis elegans |
| Q34509807 | Genetically engineered models relevant to neurodegenerative disorders: their value for understanding disease mechanisms and designing/testing experimental therapeutics |
| Q34708236 | Genetically engineered mouse models of neurodegenerative diseases |
| Q35901556 | Gradient Index Microlens Implanted in Prefrontal Cortex of Mouse Does Not Affect Behavioral Test Performance over Time |
| Q45182331 | HSP70 deficiency results in activation of c-Jun N-terminal Kinase, extracellular signal-regulated kinase, and caspase-3 in hyperosmolarity-induced apoptosis |
| Q30954808 | Highly resolved in vivo 1H NMR spectroscopy of the mouse brain at 9.4 T. |
| Q34106564 | Huntington's disease: the challenge for cell biologists |
| Q41494275 | Impaired neurogenesis is an early event in the etiology of familial Alzheimer's disease in transgenic mice |
| Q44605297 | In VivoAssessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life |
| Q46561366 | Increased bisecting and core-fucosylated N-glycans on mutant human amyloid precursor proteins |
| Q34690883 | Increased stability of Bcl-2 in HSP70-mediated protection against apoptosis induced by oxidative stress |
| Q34709557 | Induced pluripotent stem cells from familial Alzheimer's disease patients differentiate into mature neurons with amyloidogenic properties |
| Q39085704 | Inhibited apoptosis of C(2)C(1)2 myoblasts by a Eupatorium chinense var. simplicifolium root extract |
| Q43662825 | Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. |
| Q40085988 | Involvement of prostaglandin E2 in production of amyloid-beta peptides both in vitro and in vivo |
| Q34588663 | Is pharmacological prevention of Alzheimer's a realistic goal? |
| Q24655761 | Lipid rafts, cholesterol, and the brain |
| Q35946613 | Macromolecules involved in production and metabolism of beta-amyloid at the brain barriers |
| Q37069478 | MicroRNAs (miRNAs) in neurodegenerative diseases |
| Q41547602 | MicroRNAs as newer therapeutic targets: A big hope from a tiny player |
| Q33991805 | Mitochondrially targeted antioxidants and thiol reagents |
| Q36339275 | Modeling age-related diseases in Drosophila: can this fly? |
| Q33870792 | Modeling human neurodegenerative diseases in Drosophila: on a wing and a prayer. |
| Q44251907 | Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. |
| Q34856213 | Molecular determinants and thermodynamics of the amyloid precursor protein transmembrane domain implicated in Alzheimer's disease. |
| Q34338754 | Muscarinic receptor activation protects cells from apoptotic effects of DNA damage, oxidative stress, and mitochondrial inhibition |
| Q37874157 | Neurodegeneration of the retina in mouse models of Alzheimer's disease: what can we learn from the retina? |
| Q48195853 | Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism |
| Q33913155 | Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5. |
| Q33678150 | New order from neurological disorders |
| Q45300316 | Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. |
| Q24322657 | Novel cadherin-related membrane proteins, Alcadeins, enhance the X11-like protein-mediated stabilization of amyloid beta-protein precursor metabolism |
| Q44722698 | Oxidized lipoproteins, beta amyloid peptides and Alzheimer's disease |
| Q28142727 | PDZ domain-dependent suppression of NF-kappaB/p65-induced Abeta42 production by a neuron-specific X11-like protein |
| Q52577784 | Parkinson's pathology in a fly. |
| Q37258545 | Prostaglandin E2 stimulates the production of amyloid-beta peptides through internalization of the EP4 receptor. |
| Q43792416 | Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. |
| Q39796003 | Protective effect of N-glycan bisecting GlcNAc residues on beta-amyloid production in Alzheimer's disease |
| Q58030632 | Protein Aggregation |
| Q41763638 | Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold |
| Q34286115 | Protein misfolding and disease; protein refolding and therapy |
| Q24615285 | Protein phosphatase 5 protects neurons against amyloid-beta toxicity |
| Q50514598 | Proteome map of the human hippocampus. |
| Q73370517 | Redox-regulation of intrinsic prion expression in multicellular prostate tumor spheroids |
| Q22254180 | Regulation of X11L-dependent amyloid precursor protein metabolism by XB51, a novel X11L-binding protein |
| Q57089159 | Research goals in progressive supranuclear palsy |
| Q53335648 | Role of phosphorylation of Alzheimer's amyloid precursor protein during neuronal differentiation. |
| Q33680929 | Seizure disorders in mutant mice: relevance to human epilepsies |
| Q49904673 | Selection of biomarkers for HIV-1 latency by integrated analysis |
| Q35036675 | Signal transduction and neurosurvival in experimental models of brain injury |
| Q36177182 | Spontaneous murine neuroaxonal dystrophy: a model of infantile neuroaxonal dystrophy |
| Q49158701 | Structural brain aging in inbred mice: potential for genetic linkage |
| Q35065205 | Structure of gamma-secretase and its trimeric pre-activation intermediate by single-particle electron microscopy |
| Q33829008 | Targeting Abeta and tau in Alzheimer's disease, an early interim report |
| Q41830251 | Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress |
| Q42817519 | Testing the possibility to protect bovine PrPC transgenic Swiss mice against bovine PrPSc infection by DNA vaccination using recombinant plasmid vectors harboring and expressing the complete or partial cDNA sequences of bovine PrPC. |
| Q34219234 | The biochemistry of neuronal necrosis: rogue biology? |
| Q28142586 | The cerebral proteopathies |
| Q33998074 | The complex clinical and genetic classification of inherited ataxias. I. Dominant ataxias |
| Q45884689 | The emerging utility of animal models of chronic neurodegenerative diseases |
| Q31497967 | The intrinsically unstable life of DNA triplet repeats associated with human hereditary disorders |
| Q24337096 | The neuronal Ca(2+) -binding protein 2 (NECAB2) interacts with the adenosine A(2A) receptor and modulates the cell surface expression and function of the receptor |
| Q36045254 | The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration |
| Q28205399 | The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders |
| Q42104984 | The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease |
| Q34778122 | Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development |
| Q36399561 | Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies |
| Q53234560 | Ubiquitin immunochemistry as a diagnostic aid for community pathologists evaluating patients who have dementia. |
| Q35123870 | Usefulness of behavioral and electrophysiological studies in transgenic models of Alzheimer's disease |
| Q24303655 | XB51 isoforms mediate Alzheimer's beta-amyloid peptide production by X11L (X11-like protein)-dependent and -independent mechanisms |
| Q72990194 | [Understanding of molecular biology] |
| Q31962046 | beta-Amyloid efflux mediated by p-glycoprotein |
| Q35140078 | gamma-Secretase inhibitors--from molecular probes to new therapeutics? |
Search more.